Published in ACS Med Chem Lett on May 24, 2010
Development and mechanism of γ-secretase modulators for Alzheimer's disease. Biochemistry (2013) 1.18
Completely N1-selective palladium-catalyzed arylation of unsymmetric imidazoles: application to the synthesis of nilotinib. J Am Chem Soc (2011) 1.16
Synthesis and SAR Studies of Fused Oxadiazines as γ-Secretase Modulators for Treatment of Alzheimer's Disease. ACS Med Chem Lett (2012) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science (2008) 1.67
Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther (2006) 1.36
Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother (2008) 1.16
Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. Rapid Commun Mass Spectrom (2001) 1.12
Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging (2009) 1.02
Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models. Mol Pharmacol (2005) 1.01
Progress in Alzheimer's disease drug discovery: an update. Curr Opin Investig Drugs (2009) 0.94
Selective One-Pot Conversion of Carboxylic Acids into Alcohols. J Org Chem (1996) 0.94
Advances in gamma-secretase modulation. Curr Opin Drug Discov Devel (2007) 0.94
Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin Investig Drugs (1999) 0.92
Emerging and potential therapies for Alzheimer's disease. Expert Opin Ther Targets (2008) 0.87
NSAID and Alzheimer's disease; possible answers and new questions. Mol Psychiatry (2002) 0.84